Tuvatexib - VidacPharma
Alternative Names: VDA-1102Latest Information Update: 25 Sep 2024
At a glance
- Originator VidacPharma
- Class Antineoplastics; Skin disorder therapies; Small molecules
- Mechanism of Action Hexokinase inhibitors; Keratinocyte modulators; Voltage-dependent anion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Actinic keratosis; Cutaneous T-cell lymphoma
- Preclinical Solid tumours
- No development reported Squamous cell cancer
Most Recent Events
- 19 Sep 2024 VidacPharma has patent protection for Tuvatexib in the US
- 03 Jun 2024 VidacPharma receives patent allowance for Tuvatexib in the US
- 12 Mar 2024 Vidac Pharma received approval from the Helsinki Committee of the Beilinson Hospital in Israel to proceed with the second stage of a Phase IIa trial of VDA-1102 in mycosis fungoides